 According to the researchers, bicalutamide represents a potential alternative to analogues as a puberty blocker in transgender girls.Studies assessing bicalutamide as an antiandrogen in transgender women are quite limited at present.In any case, bicalutamide is clinically effective as an antiandrogen in women with hirsutism due to hyperandrogenism (including in a phase III trial) and in boys with precocious puberty, and demasculinization and feminization are well-documented effects of bicalutamide in men treated with it for prostate cancer.